Certara’s Phoenix WinNonlin Can Now be Integrated With LabLogic’s Debra Software – customers can now port ADME and protein-binding data directly from Debra to Phoenix
ST. LOUIS, MO – Dec. 10, 2013 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that it has partnered with LabLogic Systems to integrate Certara’s Phoenix® WinNonlin® pharmacokinetic (PK)/pharmacodynamic (PD) modeling and non-compartmental analysis product with LabLogic’s Debra™ Laboratory Information Management System (LIMS). Debra is used to manage data from absorption, distribution, metabolism, and excretion (ADME) and protein-binding studies. The resulting solution allows customers who are using Debra 6 as their LIMS for drug metabolism studies, to push their data directly into Phoenix WinNonlin.
“This integration will allow the two systems to communicate directly, thus removing the need to export data from Debra,” said Dr. Daniel Weiner, senior vice president and general manager at Certara. “It will increase system usability and should also provide quality control benefits.”
Debra can manage mass balance, tissue distribution, and PK results from ADME studies. With the addition of LabLogic’s Protein Binding module, Debra can also perform a comprehensive series of protein-binding assays.
Phoenix WinNonlin provides robust, intuitive modeling tools that allow researchers to visualize and analyze their PK and PK/PD data easily. It also enables them to collect all their results, including plots, tables and workflows, in a single project file. This convenient data management approach encourages results sharing and collaboration between team members.
“We developed this integration for Debra and Phoenix WinNonlin, two industry standard drug discovery software products, in direct response to customer requests,” said Huw Loaring, systems director at LabLogic. “We are always looking for ways to help our pharmaceutical customers to streamline their drug discovery process.”
LabLogic is managing customer requests for this product integration.
Certara（サターラ）について
Certara is dedicated to improving human health by delivering a broad spectrum of software products and consulting services, spanning molecular discovery to clinical development, with special focus on supporting translational approaches to drug development. A leading provider of model-based drug development tools, Certara was formed by the acquisition and integration of industry leaders Tripos®, Simcyp™, and Pharsight® Corporation. Each Certara family brand focuses on a key phase within the drug discovery and development process; combined, they offer a unique set of scientific modeling, analysis, and simulation capabilities that can enable the cross-disciplinary approaches necessary for translational science initiatives. For more information, visit www.certara.com.
About LabLogic
LabLogic Systems is a premier instrument and software provider supporting PET/nuclear medicine facilities, pharmaceutical companies, agrochemical research, universities and contract research organizations for over 30 years. Our systems for radio-HPLC, radio-TLC and other quality control instruments are designed to help streamline operations and meet with demanding compliance requirements.
Specialist applications software is central to the LabLogic portfolio of products. Designed to drive the range of instruments, interpret results and integrate with other systems, our software – which includes Laboratory Information Management Systems for ADME studies and PET production – is used widely in prestigious research facilities and recognized as the industry standard in its field. For more information, visit www.lablogic.com.
お問合せ先
James Hayden, (201) 274 6373
SVP Global Sales and Marketing
james.hayden@certara.com
LabLogic Contact:
Huw Loaring, +44-114-266-7267
Systems Director
hloaring@lablogic.com
報道機関の皆様：
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
lisa@ranahealth.com
